Clinical Trials Browser

NCT05475678 2025-01-23

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2 Recruiting

369 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Phase 2 Completed

35 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

132 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05189483 2024-02-07

Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

Phase 2 Unknown

40 enrolled

Sarcoma

NCT05624099 2023-10-19

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Phase 2 Recruiting

75 enrolled

Gastrointestinal

Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms

NCT05547737 2022-09-21

NSCLC

Unknown

500 enrolled

Thoracic

NSCLC

NCT04675866 2022-04-15

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Phase NA Unknown

46 enrolled

Gastrointestinal

Advanced Gastric Adenocarcinoma

NCT04901754 2021-12-08

CAMERA

Phase 2 Unknown

38 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Phase 2 Unknown

20 enrolled

Other solid neoplasm

Solid Tumor

NCT04102982 2020-11-02

MWA in NSCLC

Phase 2 Unknown

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04213898 2019-12-30

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Phase 1/2 Unknown

39 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Phase NA Unknown

20 enrolled

Gastrointestinal

Advanced Gastric Adenocarcinoma

NCT03986515 2019-06-14

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Phase 2 Unknown

40 enrolled

Dermatologic

Mucosal Melanoma

NCT03755115 2019-01-16

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Phase 2 Unknown

40 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage